JP2006523682A5 - - Google Patents

Info

Publication number

JP2006523682A5

JP2006523682A5 JP2006507478A JP2006507478A JP2006523682A5 JP 2006523682 A5 JP2006523682 A5 JP 2006523682A5 JP 2006507478 A JP2006507478 A JP 2006507478A JP 2006507478 A JP2006507478 A JP 2006507478A JP 2006523682 A5 JP2006523682 A5 JP 2006523682A5

Authority

JP

Japan

Prior art keywords

pharmaceutical composition

agonist

polypeptide

subject

antibody

Prior art date

2004-03-22

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Pending

Links

• Espacenet
• Global Dossier
• Discuss

• 108010074108 interleukin-21 Proteins 0.000 claims 39
• 239000008194 pharmaceutical composition Substances 0.000 claims 27
• 238000000034 method Methods 0.000 claims 26
• 239000000556 agonist Substances 0.000 claims 23
• 102100030704 Interleukin-21 Human genes 0.000 claims 22
• 102000004527 Interleukin-21 Receptors Human genes 0.000 claims 20
• 108010017411 Interleukin-21 Receptors Proteins 0.000 claims 20
• 230000001270 agonistic effect Effects 0.000 claims 12
• 201000006417 multiple sclerosis Diseases 0.000 claims 9
• FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 8
• 125000003275 alpha amino acid group Chemical group 0.000 claims 6
• 239000005557 antagonist Substances 0.000 claims 6
• 239000000427 antigen Substances 0.000 claims 6
• 102000036639 antigens Human genes 0.000 claims 6
• 108091007433 antigens Proteins 0.000 claims 6
• 239000012634 fragment Substances 0.000 claims 6
• 229940121363 anti-inflammatory agent Drugs 0.000 claims 4
• 239000002260 anti-inflammatory agent Substances 0.000 claims 4
• 208000026278 immune system disease Diseases 0.000 claims 4
• 229920001184 polypeptide Polymers 0.000 claims 4
• 102000004196 processed proteins & peptides Human genes 0.000 claims 4
• 108090000765 processed proteins & peptides Proteins 0.000 claims 4
• ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 claims 4
• 229960002930 sirolimus Drugs 0.000 claims 4
• QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 claims 4
• 102000004169 proteins and genes Human genes 0.000 claims 3
• 108090000623 proteins and genes Proteins 0.000 claims 3
• 208000024891 symptom Diseases 0.000 claims 3
• KISWVXRQTGLFGD-UHFFFAOYSA-N 2-[[2-[[6-amino-2-[[2-[[2-[[5-amino-2-[[2-[[1-[2-[[6-amino-2-[(2,5-diamino-5-oxopentanoyl)amino]hexanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-(diaminomethylideneamino)p Chemical compound C1CCN(C(=O)C(CCCN=C(N)N)NC(=O)C(CCCCN)NC(=O)C(N)CCC(N)=O)C1C(=O)NC(CO)C(=O)NC(CCC(N)=O)C(=O)NC(CCCN=C(N)N)C(=O)NC(CO)C(=O)NC(CCCCN)C(=O)NC(C(=O)NC(CC(C)C)C(O)=O)CC1=CC=C(O)C=C1 KISWVXRQTGLFGD-UHFFFAOYSA-N 0.000 claims 2
• 101001010621 Homo sapiens Interleukin-21 Proteins 0.000 claims 2
• FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims 2
• 102000047918 Myelin Basic Human genes 0.000 claims 2
• 101710107068 Myelin basic protein Proteins 0.000 claims 2
• CBPNZQVSJQDFBE-FUXHJELOSA-N Temsirolimus Chemical compound C1C[C@@H](OC(=O)C(C)(CO)CO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 CBPNZQVSJQDFBE-FUXHJELOSA-N 0.000 claims 2
• 230000007812 deficiency Effects 0.000 claims 2
• 229960000681 leflunomide Drugs 0.000 claims 2
• VHOGYURTWQBHIL-UHFFFAOYSA-N leflunomide Chemical compound O1N=CC(C(=O)NC=2C=CC(=CC=2)C(F)(F)F)=C1C VHOGYURTWQBHIL-UHFFFAOYSA-N 0.000 claims 2
• 229960000485 methotrexate Drugs 0.000 claims 2
• 229960000235 temsirolimus Drugs 0.000 claims 2
• 108010072051 Glatiramer Acetate Proteins 0.000 claims 1
• 241000282412 Homo Species 0.000 claims 1
• 241000124008 Mammalia Species 0.000 claims 1
• 208000012902 Nervous system disease Diseases 0.000 claims 1
• FHEAIOHRHQGZPC-KIWGSFCNSA-N acetic acid;(2s)-2-amino-3-(4-hydroxyphenyl)propanoic acid;(2s)-2-aminopentanedioic acid;(2s)-2-aminopropanoic acid;(2s)-2,6-diaminohexanoic acid Chemical compound CC(O)=O.C[C@H](N)C(O)=O.NCCCC[C@H](N)C(O)=O.OC(=O)[C@@H](N)CCC(O)=O.OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 FHEAIOHRHQGZPC-KIWGSFCNSA-N 0.000 claims 1
• 230000004075 alteration Effects 0.000 claims 1
• 230000001580 bacterial effect Effects 0.000 claims 1
• 210000004027 cell Anatomy 0.000 claims 1
• 210000003169 central nervous system Anatomy 0.000 claims 1
• 210000001175 cerebrospinal fluid Anatomy 0.000 claims 1
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
• 208000035475 disorder Diseases 0.000 claims 1
• 230000000694 effects Effects 0.000 claims 1
• 229960003776 glatiramer acetate Drugs 0.000 claims 1
• 238000002347 injection Methods 0.000 claims 1
• 239000007924 injection Substances 0.000 claims 1
• 108020004999 messenger RNA Proteins 0.000 claims 1
• 210000003007 myelin sheath Anatomy 0.000 claims 1
• 230000004952 protein activity Effects 0.000 claims 1
• 238000002560 therapeutic procedure Methods 0.000 claims 1